AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10938584 — intervention group
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 27
Study 9052476 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment (orchidectomy or luteinizing hormone-releasing hormone analogue)
Number of subjects: 938
Study 9052476 — intervention group
Group type: COMPARATOR
Intervention: Deferred treatment
Number of subjects: 938
Study 8336880 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-amniotic saline infusion plus intracervical Foley catheter balloon
Number of subjects: 112
Study 8336880 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin E2 vaginal gel (2.85 mg)
Number of subjects: 112
Study 3096164 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil bolus injection (n = 15) over 3 s
Number of subjects: 30
Study 3096164 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil slow injection (n = 15) over 30 s
Number of subjects: 30
Study 3096164 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine (25 mg i.v.)
Number of subjects: 30
Study 3384470 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic systolic pressure in hypertensive subjects
Number of subjects: 27
Study 3384470 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic systolic pressure in normotensive subjects
Number of subjects: 27
Study 3384470 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory and home pressures
Number of subjects: 27
Study 3384470 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic diastolic pressures
Number of subjects: 27
Study 3384470 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest correlations of the three methods
Number of subjects: 27
Study 3384470 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest correlations of ambulatory standard deviations
Number of subjects: 27
Study 31375283 — intervention group
Group type: EXPERIMENTAL
Intervention: Meatal stenosis (Group A)
Number of subjects: 206
Study 31375283 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 206
Study 31276809 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Fentanyl Sublingual Spray (FSS) (35%-45% of total daily opioid dose)
Number of subjects: 50
Study 31276809 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Fentanyl Sublingual Spray (FSS) (15%-25% of total daily opioid dose)
Number of subjects: 50
Study 31276809 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Fentanyl Sublingual Spray (FSS)
Number of subjects: 50
Study 31276809 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study 29911789 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope®
Number of subjects: 46
Study 29911789 — intervention group
Group type: COMPARATOR
Intervention: McIntosh laryngoscope
Number of subjects: 46
Study 27164764 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance band exercises 5 times a week for 8 weeks
Number of subjects: 44
Study 27164764 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 44
Study 23184506 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive dual n-back training
Number of subjects: 0
Study 23184506 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonadaptive training
Number of subjects: 0
Study 23184506 — intervention group
Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 0
Study 21813882 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous fat transplantation (Group A; 12-165 mL per session)
Number of subjects: 20
Study 21813882 — intervention group
Group type: COMPARATOR
Intervention: Adipose-derived stem cell-enriched lipografts (Group B; 8-155 mL per session)
Number of subjects: 20
Study 21813882 — intervention group
Group type: COMPARATOR
Intervention: Comparison at 18 months
Number of subjects: 20
Study 19288047 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 1869
Study 19288047 — intervention group
Group type: COMPARATOR
Intervention: Ticlopidine
Number of subjects: 1869
Study 16735482 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein preload (50 g, 1.1 MJ, 450 ml)
Number of subjects: 72
Study 16735482 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein preload (50 g, 1.1 MJ, 450 ml)
Number of subjects: 72
Study 16735482 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten protein preload (50 g, 1.1 MJ, 450 ml)
Number of subjects: 72
Study 16735482 — intervention group
Group type: COMPARATOR
Intervention: Glucose treatment
Number of subjects: 72
Study 16735482 — intervention group
Group type: EXPERIMENTAL
Intervention: All protein preloads (whey, soy, gluten)
Number of subjects: 72
Study 16735482 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting GLP-1 concentrations
Number of subjects: 72
Study 16735482 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial GLP-1 responses
Number of subjects: 72
Study 15331551 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous exenatide (0.066 pmol.kg(‐1).min(‐1))
Number of subjects: 12
Study 15331551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11359035 — intervention group
Group type: EXPERIMENTAL
Intervention: Phalangeal amplitude‐dependent speed of sound (Ad‐SOS) measurement
Number of subjects: 228
Study 11359035 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial correlations adjusted for important confounding variables
Number of subjects: 228
Study 9156366 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P (30 and 90 ng/min for 2 min)
Number of subjects: 8
Study 9156366 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary acetylcholine (10 micrograms/min for 2 min)
Number of subjects: 8
Study 9156366 — intervention group
Group type: COMPARATOR
Intervention: NG‐monomethyl‐L‐arginine (L‐NMMA) at 200 mumol
Number of subjects: 8
Study 9156366 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine (4, 8, and 16 micrograms/min for 2 min)
Number of subjects: 8
Study 9156366 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P (0.8, 1.6, and 3.2 ng/min for 2 min)
Number of subjects: 8
Study 9156366 — intervention group
Group type: COMPARATOR
Intervention: Intraarterial L‐NMMA (8 mumol/min for 5 min)
Number of subjects: 8
Study 8333471 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate depot (3.75 mg injected monthly)
Number of subjects: 270
Study 8333471 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol (800 mg administered orally daily)
Number of subjects: 270
Study 2436919 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimoprostil (prostaglandin E2 analogue)
Number of subjects: 0
Study 29965967 — intervention group
Group type: EXPERIMENTAL
Intervention: MJ8VAX (50 μg of peptide conjugate J8-DT)
Number of subjects: 10
Study 29965967 — intervention group
Group type: EXPERIMENTAL
Intervention: MJ8VAX
Number of subjects: 10
Study 29965967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 27100427 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinner-to-bed time <3 hours
Number of subjects: 917
Study 27100427 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-dinner nonwalk
Number of subjects: 917
Study 27100427 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinner-to-bed time <3 hours and post-dinner nonwalk
Number of subjects: 917
Study 27100427 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction of dinner-to-bed time and post-dinner walk
Number of subjects: 917
Study 25448661 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightweight mesh (LW)
Number of subjects: 226
Study 25448661 — intervention group
Group type: COMPARATOR
Intervention: Heavyweight mesh (HW)
Number of subjects: 226
Study 22225699 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider training with rapid diagnostic tests (RDTs)
Number of subjects: 0
Study 22225699 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced provider training with rapid diagnostic tests (RDTs)
Number of subjects: 0
Study 22225699 — intervention group
Group type: COMPARATOR
Intervention: Current practice without RDTs
Number of subjects: 0
Study 19160429 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/d for 6 months
Number of subjects: 25
Study 19160429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 17469668 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% effort
Number of subjects: 49
Study 17469668 — intervention group
Group type: COMPARATOR
Intervention: 50% effort
Number of subjects: 49
Study 15670299 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocervical brush first (564 cases)
Number of subjects: 1129
Study 15670299 — intervention group
Group type: COMPARATOR
Intervention: Spatula first (565 cases)
Number of subjects: 1129
Study 15670299 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 1129
Study 12105320 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg/d for 30 days)
Number of subjects: 18
Study 12105320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 10199318 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemented enteral formula (enriched with arginine, RNA, and omega-3 fatty acids)
Number of subjects: 206
Study 10199318 — intervention group
Group type: COMPARATOR
Intervention: Control enteral formula
Number of subjects: 206
Study 8789587 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 days/week training during TP1
Number of subjects: 19
Study 8789587 — intervention group
Group type: COMPARATOR
Intervention: 3 alternate days/week training during TP2
Number of subjects: 19
Study 8789587 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline training (S1 and S2)
Number of subjects: 19
Study 1968320 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (1.2%)
Number of subjects: 60
Study 1968320 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane (0.7%)
Number of subjects: 60
Study 1968320 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil-N2O
Number of subjects: 60
Study 6457060 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/d disodium dichloromethylene diphosphonate (Cl2MDP)
Number of subjects: 21
Study 6457060 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,600 mg/d disodium dichloromethylene diphosphonate (Cl2MDP)
Number of subjects: 21
Study 6457060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 31610101 — intervention group
Group type: EXPERIMENTAL
Intervention: BHV-0223 (40 mg)
Number of subjects: 133
Study 31610101 — intervention group
Group type: EXPERIMENTAL
Intervention: BHV-0223 (40 mg) under fed conditions
Number of subjects: 133
Study 31610101 — intervention group
Group type: COMPARATOR
Intervention: Oral riluzole tablets (50 mg)
Number of subjects: 133
Study 31000063 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanochemical Ablation (MOCA)
Number of subjects: 213
Study 31000063 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency Ablation (RFA)
Number of subjects: 213
Study 27377301 — intervention group
Group type: EXPERIMENTAL
Intervention: sirolimus- and probucol-eluting stents
Number of subjects: 311
Study 27377301 — intervention group
Group type: COMPARATOR
Intervention: zotarolimus-eluting stents
Number of subjects: 311
Study 27880997 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF+NA
Number of subjects: 32
Study 27880997 — intervention group
Group type: COMPARATOR
Intervention: ADV+NA
Number of subjects: 32
Study 24291054 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg P. emblica extract
Number of subjects: 10
Study 24291054 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg clopidogrel
Number of subjects: 10
Study 24291054 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg ecosprin
Number of subjects: 10
Study 24291054 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg P. emblica + 75 mg clopidogrel
Number of subjects: 10
Study 24291054 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg P. emblica + 75 mg ecosprin
Number of subjects: 10
Study 24291054 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg P. emblica extract (twice daily)
Number of subjects: 10
Study 24291054 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg clopidogrel (once daily)
Number of subjects: 10
Study 24291054 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg ecosprin (once daily)
Number of subjects: 10
Study 22307069 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 3903
Study 22307069 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest genetic risk score (GRS)
Number of subjects: 3903
Study 22307069 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 3903
Study 19755613 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg daily for 4 weeks
Number of subjects: 39
Study 19755613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 17218575 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercapnia (5% carbon dioxide)
Number of subjects: 30
Study 17218575 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia (40% oxygen)
Number of subjects: 30
Study 17218575 — intervention group
Group type: COMPARATOR
Intervention: Control (room air)
Number of subjects: 30
Study 15376812 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical word length measured relative to the length of other words in the list
Number of subjects: 0
Study 15376812 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition experiments with words of lengths that never occurred in a studied list
Number of subjects: 0
Study 11600564 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin treatment in subjects with null mutations
Number of subjects: 42
Study 11600564 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin treatment in subjects with defective mutations
Number of subjects: 42
Study 9637897 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (40 mg/kg/day)
Number of subjects: 113
Study 9637897 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V (lower dosage)
Number of subjects: 113
Study 8089542 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream 5%
Number of subjects: 47
Study 8089542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 2683937 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microL of levobunolol
Number of subjects: 117
Study 2683937 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 microL of levobunolol
Number of subjects: 117
Study 2683937 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microL of levobunolol
Number of subjects: 117
Study 2683937 — intervention group
Group type: COMPARATOR
Intervention: 35 microL of vehicle (control)
Number of subjects: 117
Study 1097869 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline (Ludiomil)
Number of subjects: 71
Study 1097869 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 71
Study 31956917 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher burden of baseline white matter hyperintensity (WMH)
Number of subjects: 388
Study 31956917 — intervention group
Group type: COMPARATOR
Intervention: Baseline infarcts
Number of subjects: 388
Study 31956917 — intervention group
Group type: COMPARATOR
Intervention: Baseline microbleeds
Number of subjects: 388
Study 31013190 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week scapular stabilization exercises with abdominal control feedback (n = 45)
Number of subjects: 135
Study 31013190 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week scapular stabilization exercises without abdominal control feedback (n = 45)
Number of subjects: 135
Study 31013190 — intervention group
Group type: COMPARATOR
Intervention: Active self-exercise (Control group, n = 45)
Number of subjects: 135
Study 28492789 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting lignocaine-based blood cardioplegia (single dose)
Number of subjects: 110
Study 28492789 — intervention group
Group type: COMPARATOR
Intervention: Short-acting St Thomas 1 blood cardioplegia (repeated every 20 minutes)
Number of subjects: 110
Study 25922328 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised use of facemasks for 7 days
Number of subjects: 0
Study 25922328 — intervention group
Group type: COMPARATOR
Intervention: Standard measures
Number of subjects: 0
Study 22836603 — intervention group
Group type: EXPERIMENTAL
Intervention: Reebok Core Board (RCB) during deep squat task
Number of subjects: 13
Study 22836603 — intervention group
Group type: COMPARATOR
Intervention: Ground during deep squat task
Number of subjects: 13
Study 22836603 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing weight loads (body weight, 30%RM, 60%RM)
Number of subjects: 13
Study 21913385 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound cavitation therapy (USC) using Sonoca‐180 unit
Number of subjects: 231
Study 21913385 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy (control group)
Number of subjects: 231
Study 18642029 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 30 mg im on day 1
Number of subjects: 38
Study 18642029 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 30 mg on day 1 plus Imatinib 400 mg po daily
Number of subjects: 38
Study 18642029 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin on day 1 (60 mg-90 mg/m2)
Number of subjects: 38
Study 18642029 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin on day 1, 8, 15 (20 mg-30 mg/m2) plus octreotide 30 mg on day 1 plus imatinib 400 mg po daily
Number of subjects: 38
Study 16686913 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-methionine load homocysteine values
Number of subjects: 45
Study 16686913 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate levels
Number of subjects: 45
Study 16686913 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR C677T and A1298C polymorphisms
Number of subjects: 45
Study 15633480 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB) using subdermal or peritumoral injection of vital blue dye and/or both substances together.
Number of subjects: 0
Study 15633480 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB)
Number of subjects: 0
Study 11425807 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (25 mg, orally, once daily for 9 consecutive days)
Number of subjects: 13
Study 11425807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 11425807 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib and Placebo
Number of subjects: 13
Study 9230720 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (300 micrograms)
Number of subjects: 8
Study 9230720 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide (80 micrograms)
Number of subjects: 8
Study 8574511 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam 100 micrograms/kg by jet‐injection (JI)
Number of subjects: 40
Study 8574511 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam 150 micrograms/kg by jet‐injection (JI)
Number of subjects: 40
Study 8574511 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam 200 micrograms/kg by jet‐injection (JI)
Number of subjects: 40
Study 8574511 — intervention group
Group type: COMPARATOR
Intervention: midazolam 80 micrograms/kg i.m by conventional syringe‐needle
Number of subjects: 40
Study 2203257 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (800 mg dl-alpha-tocopheryl acetate)
Number of subjects: 32
Study 393520 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release propranolol capsules 160 mg once daily
Number of subjects: 8
Study 393520 — intervention group
Group type: COMPARATOR
Intervention: Standard propranolol tablets 40 mg four times daily
Number of subjects: 8
Study 393520 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 8
Study 30951620 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotary system (PROTAPER NEXT® ‐ PTN)
Number of subjects: 48
Study 30951620 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocating system (WaveOne® ‐ WO)
Number of subjects: 48
Study 30951620 — intervention group
Group type: COMPARATOR
Intervention: Hand K‐files
Number of subjects: 48
Study 28857007 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Flexible Integrated Responsive Support Team
Number of subjects: 113
Study 28857007 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 113
Study 28500900 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells (MSC) therapy with a target dose of 1×10^6 cells/kg intravenously and 0.1×10^6 cells/kg intrathecally
Number of subjects: 22
Study 28500900 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with anti-epileptic drugs (AED)
Number of subjects: 22
Study 23562198 — intervention group
Group type: EXPERIMENTAL
Intervention: TAA HFA at 14, 110, or 440 micrograms once daily
Number of subjects: 780
Study 23562198 — intervention group
Group type: EXPERIMENTAL
Intervention: TAA CFC at 14, 110, or 440 micrograms once daily
Number of subjects: 780
Study 23562198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 780
Study 23562198 — intervention group
Group type: EXPERIMENTAL
Intervention: TAA HFA and TAA CFC formulations
Number of subjects: 780
Study 23562198 — intervention group
Group type: EXPERIMENTAL
Intervention: TAA HFA at 7 micrograms per nostril once daily
Number of subjects: 780
Study 20976495 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacker fixation (group I)
Number of subjects: 68
Study 20976495 — intervention group
Group type: COMPARATOR
Intervention: Suture fixation (group II)
Number of subjects: 68
Study 19135348 — intervention group
Group type: EXPERIMENTAL
Intervention: MK‐0359 (15mg/day)
Number of subjects: 88
Study 19135348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 17174015 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose selenium (Se+ group, 474, 316, 158 microg/day for 3 days followed by 31.6 microg/day)
Number of subjects: 40
Study 17174015 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose selenium (Se+ group)
Number of subjects: 40
Study 17174015 — intervention group
Group type: COMPARATOR
Intervention: Control group (Se- group, standard dose of 31.6 microg/day)
Number of subjects: 40
Study 15143088 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (5,000 IU, once-daily subcutaneous injection)
Number of subjects: 385